Tactile Systems Technology (TCMD) Stock
Small cap maker of compression therapy devices. Here's the price, business snapshot, and what's worth knowing about Tactile Systems Technology in October 2026.
Tactile Systems Technology, Inc. (TCMD) designs and markets pneumatic compression systems used to treat lymphoedema, chronic oedema and related circulatory conditions. Its business combines one-off device sales with recurring consumable garments, rentals and service contracts, creating a mix of upfront and recurring revenue. The company is a small‑cap medical device player (market cap ~ $329M) that relies on clinical adoption, reimbursement from insurers and distribution relationships to grow volumes. Key investor considerations include revenue growth and margin trends, cash flow and capital allocation, the pace of clinical evidence and payer coverage decisions. Competitive pressure, regulatory oversight and changes to reimbursement can materially affect outcomes, and small‑cap stocks can be volatile. This summary is educational only and not investment advice; investors should review the company’s SEC filings and consider their own risk tolerance and diversification needs before acting.
Tactile Systems Technology (TCMD) Stock Forecast
Analyst price target, next 12 months
$31.80
+35.4% vs today's $23.49
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Tactile Systems Technology have a consensus 12-month target of $31.80, above the current price of $23.49.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend strongly buying Tactile Systems stock, expecting its price to rise significantly.
Financial Health
Tactile Systems is performing well with strong revenue and cash flow, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Device + Consumables
The business blends one‑off device sales with recurring consumables and services, which can support revenue predictability—though uptake and reimbursement can vary.
Clinical Evidence Matters
Adoption by clinicians and payers often depends on clinical outcomes; positive studies can help growth, but results and timelines are uncertain.
Reimbursement & Regulation
Coverage decisions by Medicare and insurers materially affect volumes; regulatory or reimbursement shifts can quickly change the commercial outlook.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
